Drug Firm Ikaria Inc. Goes on the Block for More Than $2 Billion

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Ikaria Inc, a private equity and venture capital-backed company whose products are focused on critically ill patients, is exploring a sale that it hopes could value it at more than $2 billion, three people familiar with the matter said this week. Ikaria, whose owners include New Mountain Capital LLC, ARCH Venture Partners LP and Venrock Associates LP, is working with Morgan Stanley (MS.N) and Credit Suisse Group AG (CSGN.VX) on the possible sale, two of the people said. The sources requested anonymity because the sale process is confidential. Ikaria and Credit Suisse declined to comment, while representatives for Morgan Stanley and Ikaria's main shareholders did not respond to requests for comment.

Help employers find you! Check out all the jobs and post your resume.

Back to news